Abstract:TRAIL (Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand) is a promising candidate for cancer treatment due to its unique ability to selectively induce programmed cell death, or apoptosis, in cancer cells while sparing healthy ones. This selectivity arises from TRAIL's preferential binding to death receptors on cancer cells, triggering a cascade of events that lead to their demise. However, significant limitations in using TRAIL for cancer treatment is administration of TRAIL protein that can potentially lead to tissue toxicity (off-target), the short half-life of TRAIL in the body may necessitate frequent and sustained administration, which can pose logistical challenges for long-term treatment regimens. We have devised a novel approach to surmount these limitations by introducing the TRAIL gene directly into cancer cells, enabling them to produce TRAIL locally and subsequently trigger apoptosis. A novel gene delivery system, a bacteriophage-based particle TPA (transmorphic phage/AAV) was utilized to address these limitations. TPA is a hybrid M13 filamentous bacteriophage particle encapsulating therapeutic gene cassette with inverted terminal repeats (ITR) from adeno-associated virus (AAV). The particle also displayed a tumour targeting ligand, CDCRGDCFC (RGD4C), on its capsid (RGD4C.TPA) to target the particle to cancer cells. The RGD4C selectively binds to αvβ3 and αvβ5 integrins overexpressed on the surface of most of cancer cells but barely present on normal cells. Hepatocellular carcinoma (HCC) was chosen as a model because it has one of the lowest survival rates among cancers. We demonstrated that human HCC cell lines (Huh-7 and HepG2) expresses αvβ5 integrins receptors on their surface. These HCC cells also express death receptors, TRAIL binding receptors. We showed that targeted TPA particle carrying transmembrane TRAIL gene (RGD4C.TPA-tmTRAIL) selectively and efficiently delivered tmTRAIL gene to HCC cells resulting in production of tmTRAIL from transduced cells and subsequently induced apoptotic death of HCC cells. This tumour-targeted particle can be an excellent candidate for targeted gene therapy of HCC.

Oncolytic Adenovirus Encoding Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Inhibits the Growth and Metastasis of Triple-Negative Breast Cancer

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity Without Toxic Effects on Primary Human Hepatocytes

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29.

Anti-liver Cancer Activity of TNF-related Apoptosis-Inducing Ligand Gene and Its Bystander Effects.

[Activity of the TNF-related Apoptosis-Inducing Ligand Gene Expressed from the Htert Promoter on Colon Cancer Cell Line HT-29].

Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Oncolytic Adenovirus Zd55-Trail As A Therapy Against Cervical Cancer

[Action of Apoptosis-Induced Ligand Gene in Relation to Tumor Necrosis Factor on Human Colon Cancer Cell Line HT29].

Fiber-modified Adenoviral Vector Expressing the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene from the Human Telomerase Reverse Transcriptase Promoter Induces Apoptosis in Human Hepatocellular Carcinoma Cells

Bacteriophage-based particle carrying TNF-related apoptosis-inducing ligand (TRAIL) gene for targeted delivery to Hepatocellular carcinoma

A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma

Oncolytic Tanapoxvirus Recombinants Expressing Flagellin C or Mouse Interleukin-2 Are Capable of Regressing Human Triple-Negative Breast Cancer Xenografts in Immuno-Competent BALB/c Nude Mice

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

Ad-VT causes ovarian cancer A2780 cell death via mitochondrial apoptosis and autophagy pathways

Recombinant Oncolytic Adenovirus Combined with Cyclophosphamide Induces Synergy in the Treatment of Breast Cancer in Vitro and in Vivo

Enhanced Antitumor Efficacy of Oncolytic Vaccinia Virus Therapy Through Keratin-Mediated Delivery in Triple-Negative Breast Cancer

A New Oncolytic Adenoviral Vector Carrying Dual Tumour Suppressor Genes Shows Potent Anti-Tumour Effect

Oncolytic Adenovirus Armed with IL-24 Inhibits the Growth of Breast Cancer in Vitro and in Vivo.

Adenovirus-Mediated Combined Anti-Angiogenic and Pro-Apoptotic Gene Therapy Enhances Antitumor Efficacy in Hepatocellular Carcinoma

Anti-tumor effect of a dual cancer-specific recombinant adenovirus on ovarian cancer cells